6-Chloro-2(1-piperazinyl) quinoxaline (CPQ): action on serotonin-induced behavioral responses and interactions with chloromethamphetamine and dimethyl-meta-tyramine.
6-Chloro-2(1-piperazinyl) quinoxaline (CPQ) was examined pharmacologically and biochemically as an inhibitor of the neuronal reuptake of serotonin, dopamine and norepinephrine. The compound was 25-50 times more potent than chlorimipramine in potentiating the head-twitch response to 5-hydroxytryptophan (5-HTP) and in antagonizing p-chloromethamphetamine (PCMA)-induced depletion of brain serotonin in rats. CPQ also potentiated the forepaw clonus produced by 5HTP in rats and antagonized PCMA-induced head twitches. At dose levels 30 times those necessary to significantly affect serotoninergic systems, CPQ was ineffective in antagonizing either tetrabenazine-induced sedation in mice or the depletion of rat brain and heart norepinephrine or brain dopamine produced by 4, alpha-dimethylmeta-tyramine (H77/77). The data indicate that CPQ exhibits a high degree of potency and selectivity in inhibiting the neuronal reuptake of serotonin.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001923:Brain Chemistry / Q000187:drug effects; D004347:Drug Interactions; D005260:Female; D008297:Male; D008694:Methamphetamine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism; D009474:Neurons / Q000378:metabolism; D011810:Quinoxalines / Q000494:pharmacology*; D051381:Rats; D012701:Serotonin / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D014439:Tyramine / Q000031:analogs & derivatives* / Q000494:pharmacology
D011810:Quinoxalines; D012702:Serotonin Antagonists; D012701:Serotonin; D008694:Methamphetamine; D014439:Tyramine